Latest Hemophilia B Stories
CSL Behring Continues Improving Patient Well-Being; Key Milestone Achieved in PROLONG-9FP, Company's Recombinant Factor IX Fusion Protein Development Program KING OF PRUSSIA,
Leading gene therapy Company will partner with established market leader to develop a potential new treatment paradigm for hemophilia B PHILADELPHIA, Dec.
Timeline for Hemophilia B IND Application Filing Targeting Second Quarter 2015 RICHMOND, Calif., Sept. 10, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
Data showing improved pharmacokinetic profile to be presented at World Federation of Hemophilia Congress MELBOURNE, Australia, May 11, 2014 /PRNewswire/ -- Interim Phase II/III and
The Approval of ALPROLIX is First Significant Advance in Hemophilia B Treatment in More Than 17 Years CAMBRIDGE, MA, March 24, 2014 /CNW/ -
Global Hemophilia Market Report: 2013 Edition research studies the hemophilia market on a global scale and its various segments. Dallas, Texas (PRWEB) September
- In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.